On September 4, 2026, FDA posted an immediately-in-effect guidance titled "Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates; Guidance for Industry" (Docket No. FDA-2026-D-9571). The PDF was prepared by multiple offices in the Center for Drug Evaluation and Research (CDER) and implemented without prior public comment under 21 CFR 10.115(g)(2) and section 701(h)(1)(C)(i) of the Federal Food, Drug, and Cosmetic (FD&C) Act. The document describes two temporary enforcement policies: one for State-licensed pharmacies and Federal facilities that are not registered as outsourcing facilities, including hospital and health-system pharmacies (section 503A), and one for registered outsourcing facilities (section 503B).
FDA's press announcement, content current September 4, 2026, says the agency became aware of a potential supply gap after children's hospitals raised concerns based on discontinuation of certain standardized neonatal starter parenteral nutrition (PN) products made by two outsourcing facilities that are permanently shutting down. The guidance HTML and PDF describe that event as the expected market exit of the predominant source. Those official sentences are a supply event, not a Drug Shortage Database listing and not a roster of named firms.
Trade recaps and search summaries have already framed the action as emergency guidance that "eases compounding rules." That is the wrong RFQ. Temporary enforcement discretion is not product approval, not an emergency use authorization, and not a waiver of remaining 503A, 503B, or insanitary-conditions duties.
STARTER PARENTERAL NUTRITION REGULATORY STATUS COMPARISON MATRIX
| Regulatory Attribute | FDA-Approved Drug Product (NDA / ANDA) | Section 503B Outsourcing Temporary Discretion | Section 503A Pharmacy (Hospital / Traditional Compounder) |
|---|---|---|---|
| Legal Classification | Approved under Section 505 of the FD&C Act (21 U.S.C. 355) | Compounded drug product; not FDA-approved | Compounded drug product; not FDA-approved |
| Approved starter PN? | Guidance: none at this time | Appendix A list only, under named conditions | Appendix A list only, under five named circumstances |
| Shortage-list copy | Section 506E tracks approved finished products | Wrong frame: no approved starter PN product to copy or list | 503A prescription discretion is not a 506E listing |
| CGMP | 21 CFR Parts 210 and 211 | 21 CFR 211 still applies; only named stability / expiration points deferred | 503A CGMP exemption remains only if remaining 503A conditions are met |
| Default BUD in this document | Approved expiry dating | 30 hours room temp / 9 days refrigerated if stability and sterility are not complete | Appendix B: 30 hours room temp / 9 days refrigerated; no frozen BUD in Appendix B |
| Container-closure | Validated in the approved application | Initiate CCIT with the first batch (Appendix C) | Not the 503B first-batch CCIT condition |
| Preservative status | Per approved labeling | Single-use; no antimicrobial preservatives | Single-use; no antimicrobial preservatives |
| Formulation scope | Exact approved specification | Closed Appendix A list: 20 formulations, 250 mL | Same closed Appendix A list |
| Clock | Permanent marketing license | 180 days after publication, until March 8, 2027 | Same 180-day window, until March 8, 2027 |
A hospital pharmacy or 503B facility cannot treat FDA's temporary policy as approval of starter PN, as a Drug Shortage Database listing that authorizes copies of an approved drug, as a general exemption from 503B current good manufacturing practice (CGMP), or as open-ended authority for a 503A pharmacy to distribute customized neonatal TPN without a patient-specific prescription.
What did FDA actually issue on September 4 2026, and which clock runs to March 8 2027?
Keep the administrative dates separate. Do not collapse them into the press headline.
FDA HTML for the guidance is content current September 4, 2026, docket 2026-D-9571.
The PDF is dated September 2026, implemented immediately under 21 CFR 10.115(g)(2). Its guidance-history table records Level 1 Immediate Implementation in August 2026.
Federal Register public-inspection notice 2026-18368 was filed September 4, 2026, at 4:15 p.m. and is scheduled for publication September 9, 2026. As of this article's as-of date, that notice remains unpublished public inspection, not the official Federal Register edition.
The PDF says the enforcement policies "are intended to provide temporary flexibility for 180 days after the publication date of this guidance, until March 8, 2027." March 8, 2027 is 180 days after September 9, 2026, the scheduled Federal Register publication date—not 180 days after the September 4 press announcement.
FDA implemented the guidance without prior public comment because it determined that prior public participation was not feasible or appropriate. The stated purpose is to help ensure patient access to certain starter PN products for neonates. Guidances remain nonbinding except where they restate statutory or regulatory requirements. The document is not an emergency use authorization and does not approve a drug.
On compounded products, the PDF is direct:
Compounded drug products are not FDA-approved, which means they are not reviewed by FDA for safety, effectiveness, or quality before they reach patients. The Agency recommends FDA-approved drug products be used to treat patients whenever possible.
The introduction separately states that the potential supply disruption is particularly important because at this time there are no FDA-approved starter parenteral nutrition drug products for neonates. That sentence is the legal anchor. It is why a 506E shortage-list copy of an approved finished product is the wrong frame for this RFQ.
Footnotes 9 and 15 add a narrow grandfathering rule: drug products compounded and labeled in compliance during the enforcement-discretion period may continue to be administered through the labeled beyond-use date (BUD) after the policy expires, provided the product was distributed before the 180-day period ends. That is not permission to keep distributing after March 8, 2027. Footnote 6 adds that FDA may extend some or all of the temporary policies, update the product list, or take other steps as supply changes.
Does a 503A hospital pharmacy now have 503B-style office-use authority for any neonatal TPN, or only Appendix A bags under five named conditions?
Under section 503A of the FD&C Act (21 U.S.C. § 353a) and FDA's December 2016 guidance Prescription Requirement Under Section 503A of the Federal Food, Drug, and Cosmetic Act, one condition of the 503A exemptions from new-drug approval (section 505), adequate directions for use (section 502(f)(1)), and CGMP (section 501(a)(2)(B)) is that each drug product be compounded for an identified individual patient based on a valid prescription order. The starter-PN PDF repeats that the prescription requirement is a critical mechanism distinguishing 503A compounding from conventional manufacturing and from 503B outsourcing facilities.
Section III is a temporary policy. For 180 days after publication, until March 8, 2027, FDA does not intend to take action against a State-licensed pharmacy or Federal facility that is not registered as an outsourcing facility, including a hospital or health-system pharmacy, for providing a compounded drug to a hospital or health system without obtaining a patient-specific prescription, if all of the following circumstances are present:
503A TEMPORARY COMPOUNDING DISCRETION: FIVE CIRCUMSTANCES
| Circumstance | Guidance Standard | What the RFQ should record |
|---|---|---|
| (1) Appendix A | Product appears on the Appendix A list | Closed list of 20 starter PN formulations, all 250 mL. Not any custom neonatal TPN. |
| (2) Appendix B BUD | Labeled with a default BUD in accordance with Appendix B | Appendix B table: 30 hours at 20-25 C, 9 days at 2-8 C. No frozen BUD in this table. Shorter if literature says the admixture is not stable for those windows. |
| (3) Single-use, no preservatives | Single-use only; no antimicrobial preservatives | Guidance cites neonatal safety concerns with antimicrobial preservatives. No multi-dose containers. |
| (4) State authorities | State compounding authorities in the pharmacy state (and, if different, the hospital state) are aware and do not object | "Aware" and "do not object"—not federal preemption, and not a conversion into 503B. FDA recommends consulting State authorities on local requirements. |
| (5) Remaining law | Other 503A and FD&C Act requirements are met | Includes section 501(a)(2)(A) insanitary conditions. Discretion does not authorize insanitary compounding. |
This is not a conversion of a 503A pharmacy into a 503B outsourcing facility. It does not authorize batching custom, multi-ingredient TPN for general inventory. If the product is not on Appendix A, uses a volume other than 250 mL, uses a longer BUD than Appendix B, contains a preservative, or is provided over a State board's objection, this section III policy does not apply. Ordinary 503A patient-specific compounding of formulas outside Appendix A is a different question; this document does not authorize those formulas as non-patient-specific floor stock.
Appendix A is a closed list for the purposes of these temporary policies. FDA intends to update it as appropriate. The table contains 20 numbered formulations, all 250 mL bags, built from pediatric-specific amino acids plus dextrose 5% or 10%, with or without calcium gluconate and with or without heparin. This article does not republish the milligram table. Those rows are not compounding instructions, not neonatal dosing, and not FDA-approved finished products.
Appendix A footnotes cite example component amino-acid labels—Aminosyn-PF 7% (NDA 019398), Aminosyn-PF 10% (NDA 019492), Premasol 10% (ANDA 075880), and TrophAmine 10% (NDA 019018)—as pediatric-specific amino-acid sources. Those NDAs and ANDAs are concentrated amino-acid injections, not approved starter PN admixtures.
Appendix B, for 503A compounders, lists only two storage windows for aseptically processed neonatal starter PN: 30 hours at controlled room temperature (20°C to 25°C) and 9 days refrigerated (2°C to 8°C). There is no frozen BUD in Appendix B. A footnote says a shorter BUD should be used if literature or similar approved labeling indicates the product may not be physicochemically stable for the default period, and it points to ASPEN PN compounding literature. Footnote 10 tells pharmacies to consider storage and handling conditions per United States Pharmacopeia standards. That is not a statement that Appendix B restates USP <797> "high-risk" defaults.
Independence from the October 2021 hospital compounding draft
Footnote 7 is the comparison that current recaps skip:
The policy in this guidance is separate from FDA's previously issued draft guidance for industry Hospital and Health System Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (October 2021) (when final, this guidance will represent the FDA's current thinking on this topic) and does not include a condition for use within 24 hours.
The October 2021 document is still draft, not for implementation. Its Part 1 policy would generally not take action on the 503A prescription requirement when compounded drugs are administered only to patients within the hospital or health system and are used or discarded within 24 hours of transfer out of the pharmacy. That 24-hour clock is transfer-out-of-pharmacy, not "within 24 hours of compounding," and the 2021 draft does not restore the 2016 draft's 1-mile radius. Do not import the 2016 mile-radius condition into either the 2021 draft or this 2026 starter-PN policy. Under section III, Appendix A bags may be provided to a hospital or health system under the Appendix B 30-hour / 9-day defaults without that 24-hour condition—if the other four circumstances are also present, including State non-objection.
FDA generally expects hospitals and health systems to maintain records of the supplying entity and of patients who receive the compounded products, and to provide pharmacies, to the extent allowed by law, records identifying patients to whom the products were administered.
Does 503B enforcement discretion on bulk substances and stability/expiration dates waive CGMP, insanitary-conditions, or container-closure integrity testing?
Section IV is narrower than "eased compounding rules." For 180 days after publication, until March 8, 2027, FDA does not intend to take action against an outsourcing facility for using a bulk drug substance that is not otherwise permitted under section 503B(a)(2)(A), or for not meeting CGMP requirements with regard to product stability testing and the establishment of an expiration date, when all of the listed circumstances are present.
Section 503B(a)(2)(A) is the 503B Bulks List condition for compounding from bulk drug substances. Section 503B(a)(2)(B) is a different bulk-substance alternative: a bulk that is not on that list may be used if the drug compounded from that bulk appears on FDA's shortage list at the time of compounding, distribution, and dispensing. The "essentially a copy of one or more approved drugs" condition is separate again (section 503B(a)(5)). This guidance's 503B discretion is written against 503B(a)(2)(A) plus named stability/expiration CGMP points. It is not a finding that starter PN is a 506E-listed approved product.
503B TEMPORARY ENFORCEMENT DISCRETION: TARGETED RELIEF VS REMAINING CGMP
| Named discretion | Boundary in the September 2026 PDF |
|---|---|
| Bulk substances (503B(a)(2)(A)) | Discretion for using a bulk not otherwise permitted under 503B(a)(2)(A) to compound an Appendix A product. Other 503B conditions still apply. |
| Stability testing and expiration dating | Discretion under 21 CFR 211.166 and 211.137 when Appendix C and D conditions are met, including default BUD of not more than 30 hours room temperature and not more than 9 days refrigerated when a stability study and sterility test have not been completed before release. |
| Remaining CGMP | Not waived. Aseptic processing, remaining Part 211 duties, and section 501(a)(2)(A) insanitary-conditions adulteration still apply. |
| Container-closure integrity | Circumstance (4): the outsourcing facility initiates CCIT with the first batch. Appendix C cites USP <1207> and allows an initial unaged test at release, with aged-sample testing initiated on that first batch. |
| 5,000-unit aggregate trigger | Initiate limited stability testing once aggregate batch size is expected to exceed 5,000 units (immediate containers over the 6-month 503B product report period). Default BUDs are not the large-batch pathway. |
| USP / FD&C Act overlay | Circumstance (5): other 503B and FD&C Act requirements. Section 501(b) still requires a USP-recognized drug to meet monograph standards or be labeled to show how it differs. |
Default BUDs in Appendix D apply when a stability study and a sterility test have not been completed before release. That sentence is the opposite of a claim that a 30-hour / 9-day label proves completed CGMP stability or completed USP <71> sterility. The RFQ should ask which clock the lot is on: default BUD (testing not complete) or a longer dating supported by limited stability testing under Appendix D. Assigning the default BUD does not mean 21 CFR 211.166 studies are finished. For aggregate production expected to exceed 5,000 units, the facility is to initiate limited stability testing; while that testing is underway, the PDF says the facility can continue to use the default BUD until testing is complete. If at any time during a 6-month reporting period the total exceeds 5,000 units, the small-batch default-BUD conditions no longer apply unless testing has been initiated.
Appendix C is explicit that, except for batch-size provisions, Appendices C and D are consistent with FDA's January 2020 draft CGMP guidance for 503B outsourcing facilities. That draft is not final. Do not treat it, or this temporary overlay, as a repeal of 21 CFR Part 211.
This article does not specify a CCIT method. Appendix C points to USP <1207> Package Integrity Evaluation—Sterile Products for that testing overlay.
Why is the Drug Shortage Database copy pathway the wrong legal frame when there is no FDA-approved starter PN product?
Hospitals often treat 503B supply as a bridge when an approved sterile injectable is in shortage. Two different 503B conditions can look like that bridge:
Section 503B(a)(2)(B) allows a bulk that is not on the 503B Bulks List if the compounded drug is on the shortage list at compounding, distribution, and dispensing.
Section 503B(a)(5) restricts compounding a drug that is essentially a copy of one or more approved drugs, with a shortage-related exception in the statute's copy definition.
Both depend on an approved-product / shortage-list architecture. The starter-PN PDF's introduction says there are no FDA-approved starter parenteral nutrition drug products for neonates. FDA did not rest this action on a 506E listing of an approved starter PN bag. It issued immediately-in-effect enforcement discretion for a closed Appendix A list, for 180 days.
STATUTORY PATHWAY DISCONNECT: SHORTAGE-LIST COPY VS STARTER PN DISCRETION
| Regulatory Element | Standard shortage / copy architecture | September 2026 starter PN policy |
|---|---|---|
| Authority | 503B(a)(2)(B) (off-list bulk if the compounded drug is on shortage list); 503B(a)(5) copy condition | 21 CFR 10.115(g)(2) temporary guidance; 503B discretion vs 503B(a)(2)(A) and named stability/expiration CGMP points |
| Prerequisite | An approved drug and/or a shortage- list listing | No FDA-approved starter PN product; Appendix A is a temporary policy list |
| Clock | Shortage-list status can change when supply recovers | Independent 180-day clock until March 8, 2027, unless FDA extends or withdraws it |
| Trigger | Manufacturer 506C notice and CDER shortage-staff listing | Predominant-source market exit; press: two outsourcing facilities permanently shutting down. Not a 506E row. |
The FDA drug-shortage-list reading workflow still owns how to read status, availability, and 506C fields. This page does not treat a live API pull as proof that a starter-PN row is absent; the openFDA shortages endpoint used in this research pass returned HTTP 404. The legal point does not require that pull: FDA's own PDF says there is no approved starter PN product. Component shortages of potassium phosphates or sodium chloride, discussed in the FDA shortage census, are different entities from a 250 mL starter PN admixture.
The oncology 503B bridge described in the cisplatin and carboplatin shortage analysis and in oncology injectable shortage and 503B contracting is the contrast: those pages concern copies of approved injectables. The sterile-injectable shortage capacity ledger explains why another ANDA often fails to restore sterile capacity. Starter PN never had that ANDA/NDA finished-product starting point.
How does this starter-PN clock differ from shortage-list, peptide, GLP-1, and 503B warning-letter pages?
This page is the starter-PN 503A/503B matrix. Adjacent PharmaDossier clocks stay as links, not retells:
How to read the FDA drug shortage list owns 506E field literacy.
What's in short supply on the FDA list owns the shortage census, including pediatric category counts.
The sterile-injectable shortage capacity ledger owns ANDA-versus-capacity math.
503A wellness-peptide bulk-list votes owns advisory PCAC votes that still need rulemaking. This page is immediately-in-effect discretion for a closed sterile-bag list.
The compounded GLP-1 to FDA-approved switch is the opposite story: approved products exist, the shortage resolved, and compounding discretion ended. Starter PN has no approved product and new temporary discretion. Structure 503B and hospital contracts with a March 8, 2027 off-ramp unless FDA extends the policy.
FDA warning letters by the numbers owns the letter census and already names Central Admixture Pharmacy Services (CAPS) in PN-bag quality context. This page does not treat that census as identification of the two facilities exiting the starter-PN market.
PreCheck Type V is not a PAI is a new-facility engagement pilot. This page is compounding discretion after a 503B market exit.
Annex 1 CCS versus FDA 2004 aseptic RFQ owns commercial sterile-line documents, not 503A/503B compounding.
PN admixtures are nutrient-rich and have a long inspection history around sterility assurance. The temporary policy does not create a quality holiday. Section 501(a)(2)(A) still deems a drug adulterated if prepared, packed, or held under insanitary conditions. FDA's November 2020 Insanitary Conditions at Compounding Facilities guidance remains the overlay.
Hospital sourcing checklist: what to put in the quality agreement
Use the guidance as an onboarding packet, not as a compounding worksheet and not as a ranking of 503B vendors.
HEALTH-SYSTEM TECHNICAL AUDIT CHECKLIST: STARTER PN ONBOARDING
| Audit domain | Guidance-backed standard | File to keep |
|---|---|---|
| 1. Appendix A identity | One of the 20 listed 250 mL formulations; not a custom TPN | Batch record identifying which Appendix A row, without using this article as the formula. |
| 2. 503A vs 503B clock | 503A: five circumstances, including State non-objection. 503B: (a)(2)(A) and stability / expiry discretion only. | Registration status; which section of the PDF the supplier is relying on. |
| 3. BUD clock | 30 hours room temp / 9 days refrigerated defaults; no Appendix B frozen dating. | Labeled BUD and whether the lot is on default dating (stability/sterility not complete) or longer limited-testing dating. |
| 4. 503B CCIT | Initiate container-closure integrity testing with the first batch | First-batch CCIT initiation record; USP <1207> method as used by the facility, not a method invented here. |
| 5. 5,000-unit trigger | Limited stability testing once aggregate batch size is expected to exceed 5,000 units | 6-month aggregate unit count vs 5,000 and the stability-testing protocol if the threshold is in play. |
| 6. Preservative / container | Single-use; no antimicrobial preservatives | Labeling. |
| 7. State authorities (503A) | Aware and do not object | Evidence of awareness/non-objection, not a claim of federal preemption. |
| 8. Off-ramp | 180 days until March 8, 2027; administration through labeled BUD only if distributed before the period ends | Contract language for expiry, FDA list updates, and post-March 8 supply. |
Frequently Asked Questions
If two 503B facilities are shutting down, are starter PN bags now on the FDA Drug Shortage Database?
Not on the strength of this guidance. FDA's press announcement describes a potential supply gap from discontinuation of compounded standardized bags. The PDF states there are no FDA-approved starter PN drug products for neonates. Section 506E is the wrong legal frame for copying an approved finished starter PN product that does not exist. This article does not treat a failed openFDA shortages-API call as an independent census of the public shortage database.
Can a 503A pharmacy compound starter PN for hospital floor stock without a patient-specific prescription after this guidance?
Only if all five section III circumstances are present: Appendix A identity, Appendix B default BUD, single-use without antimicrobial preservatives, State authorities aware and not objecting, and remaining 503A and FD&C Act requirements, including insanitary-conditions. Custom formulas, other volumes, or longer BUDs are outside this discretion. A hospital that already compounds patient-specific PN under ordinary 503A may not need the office-use policy.
Does the 30-hour / 9-day BUD mean a 503B has passed CGMP stability studies?
No. For 503B, those defaults apply when a stability study and a sterility test have not been completed before release. They are conservative dating under enforcement discretion, not proof that 21 CFR 211.166 work is done. If aggregate production is expected to exceed 5,000 units, limited stability testing is to be initiated. Appendix B for 503A has the same 30-hour / 9-day pair and does not include a 45-day frozen BUD.
Are Aminosyn-PF, Premasol, or TrophAmine themselves the approved starter PN products?
No. They are FDA-approved pediatric amino-acid components cited in Appendix A footnotes. A finished starter PN product in this policy is a 250 mL admixture on the Appendix A list. FDA states there are currently no FDA-approved finished starter parenteral nutrition drug products for neonates.
Sources
U.S. Food and Drug Administration (CDER). Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates; Guidance for Industry. Docket No. FDA-2026-D-9571. September 2026. https://www.fda.gov/media/194633/download
U.S. Food and Drug Administration. Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates (Guidance Landing Page). Content current September 4, 2026. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/temporary-policies-compounding-certain-starter-parenteral-nutrition-drug-products-neonates
U.S. Food and Drug Administration. FDA Takes Steps to Maintain Newborn Access to Life-Saving Starter Nutrition Products (Press Announcement). Content current September 4, 2026. https://www.fda.gov/news-events/press-announcements/fda-takes-steps-maintain-newborn-access-life-saving-starter-nutrition-products
Office of the Federal Register. Guidance: Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates (Public Inspection Notice 2026-18368). Filed September 4, 2026, at 4:15 p.m.; scheduled for publication September 9, 2026. https://www.federalregister.gov/public-inspection/2026-18368/guidance-temporary-policies-for-compounding-certain-starter-parenteral-nutrition-drug-products-for
U.S. Food and Drug Administration. Prescription Requirement Under Section 503A of the Federal Food, Drug, and Cosmetic Act; Guidance for Industry. Docket No. FDA-2016-D-0269. December 2016 (content current August 24, 2018). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/prescription-requirement-under-section-503a-federal-food-drug-and-cosmetic-act-guidance-industry
U.S. Food and Drug Administration. Insanitary Conditions at Compounding Facilities; Guidance for Industry. November 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/insanitary-conditions-compounding-facilities-guidance-industry
U.S. Food and Drug Administration. Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act (Draft Guidance). January 2020 (content current January 7, 2021). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/current-good-manufacturing-practice-guidance-human-drug-compounding-outsourcing-facilities-under
U.S. Food and Drug Administration. Hospital and Health System Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (Draft Guidance). October 2021. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hospital-and-health-system-compounding-under-section-503a-federal-food-drug-and-cosmetic-act
U.S. Food and Drug Administration. Information for Outsourcing Facilities. Content current March 29, 2022. https://www.fda.gov/drugs/human-drug-compounding/information-outsourcing-facilities
U.S. Food and Drug Administration. 503B Bulk Drug Substances List. https://www.fda.gov/drugs/human-drug-compounding/503b-bulk-drug-substances-list
U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503B of the FD&C Act. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act
U.S. Food and Drug Administration. Drug Shortages: Drug Safety and Availability. Content current July 15, 2026. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
